PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19900123-2	2010	The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate has been approved as the first-line choice of therapy for this group of patients, while the RTK inhibitor, sunitinib malate, has been approved for the treatment of GIST after disease progression or intolerance to imatinib.	Imatinib Mesylate	45-62	ret proto-oncogene	Homo sapiens	4-28	
19900123-2	2010	The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate has been approved as the first-line choice of therapy for this group of patients, while the RTK inhibitor, sunitinib malate, has been approved for the treatment of GIST after disease progression or intolerance to imatinib.	Imatinib Mesylate	45-62	ret proto-oncogene	Homo sapiens	30-33	
19900123-2	2010	The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate has been approved as the first-line choice of therapy for this group of patients, while the RTK inhibitor, sunitinib malate, has been approved for the treatment of GIST after disease progression or intolerance to imatinib.	Imatinib Mesylate	45-53	ret proto-oncogene	Homo sapiens	4-28	
19900123-2	2010	The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate has been approved as the first-line choice of therapy for this group of patients, while the RTK inhibitor, sunitinib malate, has been approved for the treatment of GIST after disease progression or intolerance to imatinib.	Imatinib Mesylate	45-53	ret proto-oncogene	Homo sapiens	30-33